Gaspard, U., Taziaux, M., Jost, M., Coelingh Bennink, H. J. T., Utian, W. H., Lobo, R. A., & Foidart, J.-M. (2023). A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2—vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life. Menopause, 30(5), 480–489. https://doi.org/10.1097/gme.0000000000002167

Douxfils, J., Gaspard, U., Taziaux, M., Jost, M., Bouvy, C., Lobo, R. A., Utian, W. H., & Foidart, J.-M. (2022). Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women. Climacteric, 26(1), 55–63. https://doi.org/10.1080/13697137.2022.2139599

Kaunitz, A. M., Achilles, S. L., Zatik, J., Weyers, S., Piltonen, T., Suturina, L., Apolikhina, I., Bouchard, C., Chen, M. J., Jensen, J. T., Westhoff, C. L., Jost, M., Foidart, J. M., & Creinin, M. D. (2022). Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol/drospirenone on bleeding patterns in healthy women. Contraception, 116, 29–36. https://doi.org/10.1016/j.contraception.2022.07.010

Gérard, C., Arnal, J.-F., Jost, M., Douxfils, J., Lenfant, F., Fontaine, C., Houtman, R., Archer, D. F., Reid, R. L., Lobo, R. A., Gaspard, U., Coelingh Bennink, H. J. T., Creinin, M. D., & Foidart, J.-M. (2022). Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Review of Clinical Pharmacology, 15(2), 121–137. https://doi.org/10.1080/17512433.2022.2054413